Core Viewpoint - The company reported a significant decline in both revenue and profit for the six months ending September 30, 2025, indicating challenges in its operational performance and market conditions [1] Financial Performance - The company recorded revenue of HKD 1.9306 billion, a year-on-year decrease of 6.4% [1] - Net profit after tax fell to HKD 4.2 million, down 89.5% compared to the previous year [1] - The loss attributable to shareholders was HKD 10.3 million, contrasting with a profit of HKD 14.1 million in the same period last year [1] Operational Challenges - The decline in profitability is primarily attributed to reduced revenue and sales, leading to lower operational leverage across major business segments [1] - The shift in service offerings towards lower-margin categories and the absence of income from previously sold medical assets further impacted profitability [1] Market Conditions - Sales amounted to HKD 1.9382 billion, representing a 7.0% decrease year-on-year [1] - Local consumer sentiment remains weak, with trends showing Hong Kong residents continuing to consume medical and wellness services in mainland China and an increase in outbound travel [1] - The strategic sale of several medical assets in the second half of the previous fiscal year negatively affected revenue performance [1]
医思健康(02138.HK)上半年盈转亏至1030万港元